Sequoia-backed in-vitro diagnosis focused biomedicine company Shenzhen New Industries Biomedical Engineering Co., Ltd (also known as Snibe) has kicked off its IPO subscription exercise targeting to raise 1.29 billion yuan ($183 million) on the ChiNext board of the Shenzhen Stock Exchange.
Snibe’s IPO application secured the approval of the China Securities Regulatory Commission on April 17.
